MyFinsight
Home
About
Contact
dnqaf: the income statement
Download
Download image
Net loss and
comprehensive loss
-$152,594,000
Loss from operations
-$152,594,000
Total operating
expenses
$152,594,000
General and
administrative
$151,451,000
Research and development
$1,143,000
Back
Back
Income Statement
source: myfinsight.com
Semnur Pharmaceuticals, Inc. (DNQAF)
Semnur Pharmaceuticals, Inc. (DNQAF)